Atıl Avcı

Atıl Avcı

Auto-generated profile, based on publicly available information

Atıl Avcı

Department of Dermatology, Kayseri University Faculty of Medicine, Kayseri, Turkey

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
RERagip Ertas
Ragip Ertas
KOKemal Ozyurt
Kemal Ozyurt
EOEmin Ozlu
Emin Ozlu
YUYilmaz Ulas
Yilmaz Ulas
AAAtil Avci
Atil Avci
MMMarcus Maurer
Marcus Maurer

12 December 2018 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
RERagıp ERTAŞ
Ragıp ERTAŞ
KÖKemal Özyurt
Kemal Özyurt
CKCigdem Karakukcu
Cigdem Karakukcu
MAMuhammet Reşat AKKUŞ
Muhammet Reşat AKKUŞ
EÖEmin Özlü
Emin Özlü
MAMustafa Atasoy
Mustafa Atasoy
Background/aim: Spontaneous wheals and/or angioedema lasting longer than six weeks are described as chronic spontaneous urticaria (CSU). Omalizumab is used for the treatment of antihistamine-resistant CSU. The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), mean platelet volume (MPV), and platelet distribution width (PDW) are considered important indicators of inflammation and platelet activation in chronic diseases. We aimed to determine the NLR, PLR, MPV, and PDW levels in patients with CSU compared with healthy controls. We also aimed to investigate the effects of omalizumab therapy on these parameters in CSU patients. Materials and methods: This hospital-based, retrospective study included 143 patients with CSU and 132 healthy controls with a mean age of 40.0 +/- 13.17 and 42.0 +/- 16.34, respectively. Patients with equal or higher-than-baseline UAS scores at week 12 of omalizumab treatment were considered nonresponders, others were considered responders. We analyzed the neutrophils, lymphocytes, platelet counts, NLR, PLR, MPV, and PDW before, during, and after omalizumab treatment and compared the results with those of healthy controls. Results: CSU patients presented higher baseline MPV (P = 0.035) and lower baseline PDW values (P < 0.001) than healthy controls. There were statistically significant increases in the MPV (P < 0.001), MPV/platelet count (P = 0.005), and PDW (P = 0.003) and there was a statistically significant decrease in the NLR (P = 0.018) during omalizumab treatment. The percent increase of MPV was low in nonresponders (P = 0.009). Nonresponders had lower PDW values than responders (P = 0.040). Conclusion: The increase in the MPV and PDW may be due to platelet activation during omalizumab treatment. The decrease in the NLR may be regarded as an antiinflammatory effect of omalizumab. The effect of omalizumab on platelet and inflammatory markers may be used to discriminate the responders from nonresponders.

9 February 2026 in Indian Dermatology Online Journal
Verified
Journal Article
Open access
FÇFurkan Çalıcıoğlu
Furkan Çalıcıoğlu
AAAtıl Avcı
Atıl Avcı
ATAyse Tenk
Ayse Tenk
YTYücel Tekin
Yücel Tekin

11 March 2024 in Journal of Anatolian Medical Research
Verified
Journal Article
Closed access
FÇFurkan Çalıcıoğlu
Furkan Çalıcıoğlu
AAAtıl Avcı
Atıl Avcı
RERagıp Ertaş
Ragıp Ertaş
YUYılmaz Ulaş
Yılmaz Ulaş
Özet : Atopik dermatit (AD); en sık çocuklarda görülen kronik, kaşıntılı, inflamatuar bir cilt hastalığıdır. Genetik ve çevresel faktörlerin etkisiyle ciltte meydana gelen hastalık, genellikle bebeklik döneminden itibaren bulgu vermeye başlar. Ekzema, enfeksiyonlar, kaşıntı, kaşıntıya bağlı ortaya çıkan uyku bozuklukları hastaların hayat kalitesini doğrudan ve olumsuz etkilemektedir. Amaç: Dermatologlar AD tanısında ve tedavisinde genellikle primer hekimlerdir; ancak eşlik eden/edebilecek komorbiditeler nedeniyle tedaviler multidisipliner bir yaklaşımla ele alınmalıdır. AD patofizyolojisini güncel çalışmalarla ve son verilerle ortaya koymak, sıklığı artan vakaların tedavisinin daha bilinçli ve rasyonel sürdürülmesinde klinisyenlere yardımcı olmak istemekteyiz. Gereç ve yöntem: AD patogenezi ile ilgili özellikle son 5 yılda yapılan çalışmalar; Pubmed, Uptodate ve Clinicalkey üzerinden taranmıştır. Veriler, ulaşılan sonuçlar birleştirilerek tablolarla ve figürlerle özetlenmiştir. Bulgular: AD’de akut dönemde Th2, kronik dönemde Th1 yanıtı baskındır. Epidermal bariyer disfonksiyonu ve kuruluk; özellikle IL-2,4,5,13,17,22,31,33 etkisiyle ve JAK-STAT hücre içi sinyal iletim yolaklarıyla ortaya çıkar. Sonuç: AD patogenezinde; inflamasyonda IL-4, IL-5, IL-13 ile birlikte IL-22 ve IL-31 de önemli rol oynamaktadır.Kaşıntının oluşmasında ve tetikleyicilere hassasiyetin artmasında görevli bu mediatörler, yeni tedavi hedeflerini oluşturmaktadır.Th1,Th17 ve Th22; diğer hücrelerle birlikte inflamasyon yanıtını derinleştiren kilit hücrelerdir.

4 March 2026 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
EÜEsranur Ünal
Esranur Ünal
BPBeste Pakırdaşı
Beste Pakırdaşı
SESelma Emre
Selma Emre
MYMuhammed Burak Yücel
Muhammed Burak Yücel
BCBurak Celik
Burak Celik
OYOrhan Yıldız
Orhan Yıldız
Real-world evidence regarding biologic therapy in geriatric psoriasis is limited, particularly concerning systemic inflammatory burden and infection-related safety. This study evaluates the clinical efficacy of biologic therapy and its impact on systemic inflammatory indices while emphasizing safety related to hepatitis B virus (HBV) serology and tuberculosis screening. We conducted a retrospective analysis of eighty biologic-naïve patients aged 65 years and older with plaque psoriasis undergoing biologic therapy. Patients were categorized by biologic class: tumor necrosis factor-α (TNF-α) inhibitors, interleukin-17 inhibitors, an interleukin-12/23 inhibitor, and interleukin-23 inhibitors. The primary outcomes included changes in Psoriasis Area and Severity Index (PASI) scores and blood count-derived inflammatory indices over time (baseline and 6 months). Secondary outcomes encompassed changes in HBV serologic status and QuantiFERON-TB (QFT) results. Data analysis utilized longitudinal mixed-effects models for repeated measures. Blood count-derived inflammatory indices, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), were assessed at baseline and 6 months, alongside HBV serology and QFT results. PASI scores demonstrated significant improvement over time (p < 0.001), with no notable differences among biologic classes after adjusting for baseline covariates. Significant time effects were observed for all inflammatory indices (all p < 0.001), with significant group × time interactions noted for SII and NLR (both p < 0.05). Variability in HBV serologic markers and QFT results was observed during follow-up; however, no cases of active tuberculosis or clinically overt hepatitis were identified. In conclusion, biologic therapy led to substantial clinical improvement in geriatric psoriasis, accompanied by reductions in systemic inflammatory indices over a 6-month period, without evidence of clinically overt hepatitis or active tuberculosis during follow-up.

1 July 2026 in Acibadem Universitesi Saglik Bilimleri Dergisi
Verified
Journal Article
Open access
OŞOrhan Şen
Orhan Şen
AAAtıl Avcı
Atıl Avcı
Purpose: We set out to quantify conventional (NLR, PLR) alongside newer multicellular inflammatory indices (SII, SIRI, AISI) in acne vulgaris (AV), and to determine how closely each tracks clinical severity. Materials and Methods: Records of 230 individuals carrying a clinical AV diagnosis were reviewed retrospectively against 265 controls frequency-matched for age and sex, yielding a study population of 495. Within the AV arm, cases were assigned to mild, moderate, or severe categories. The five indices were derived from routinely obtained blood count parameters and compared across arms.Results: Four of the five indices — NLR, SIRI, AISI and SII — separated the AV arm from controls (p